Zhijia Yan, Yongli Du, Haibin Zhang, Yong Zheng, Huiting Lv, Ning Dong and Fang He
RSC Med. Chem., 2023,14, 1629-1644
Abstract
Structural optimization progress and future research directions of CDK12 inhibitors.
Pompom Ghosh, Maximilian Schmitz, Thiyagamurthy Pandurangan, Solomon Tadesse Zeleke, Sean Chin Chan, John Mosior, Luxin Sun, Vinayak Palve, Dylan Grassie, Kanchan Anand, Sylvia Frydman, William R. Roush, Ernst Schönbrunn, Matthias Geyer, Derek Duckett and Andrii Monastyrskyi
RSC Chem. Biol., 2025,6, 36-55
Abstract
De novo design of molecular glues transforming CDK12 inhibitors, including dinaciclib, into cyclin K degraders.
Yasmin Y. Omar, Ghada F. Elmasry, Dina S. El-kady, Ahmed A. Abd-Rabou, Samir M. El-Moghazy, Fadi M. Awadallah, Gamal A. Elmegeed and Ghada H. Elsayed
RSC Med. Chem., 2026, Advance Article
Abstract
This study developed novel progesterone-based CDK8 inhibitors and demonstrated their anticancer activity against A549 cells in CS-PEG nanoform, supported by gene expression analysis, CDK8 inhibition, and molecular docking studies.
Yumeng Wang, Cencen Lei, Quan Wang, Xingxing Zhang, Liping Zhi and Xinhua Liu
RSC Med. Chem., 2024,15, 3180-3195
Abstract
A new compound exhibiting excellent inhibitory activity against CDK8 was discovered. The mechanism was explored.
Thomas M. A. Barlow, Ilse Rooman and Steven Ballet
RSC Med. Chem., 2025,16, 3362-3385
Abstract
Here, we look at recent efforts towards the discovery and optimisation of small-molecules targeting the constellation of mitotic kinases for the treatment of pancreatic cancer.